Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.59−0.07 (-10.00%)
Close on Nov 13, 2026Market cap $1.07MP/E –Yield –
Aptevo Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Aptevo Therapeutics's enterprise value was -$8.72M on Nov 11, 2026, against -$2.01M a year earlier. Over the last 5 years it ranged from -$17.36M to $33.85B, with a median of $31.97M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$8.72M | – |
| 2025 | Dec 31, 2025 | -$13.83M | -143.3% |
| 2024 | Dec 31, 2024 | $31.97M | -98.6% |
| 2023 | Dec 29, 2023 | $2.28B | -78.0% |
| 2022 | Dec 30, 2022 | $10.37B | -69.4% |
| 2021 | Dec 31, 2021 | $33.85B | -67.5% |
| 2020 | Dec 31, 2020 | $104.21B | +400.1% |
| 2019 | Dec 31, 2019 | $20.84B | +2.9% |
| 2018 | Dec 31, 2018 | $20.25B | -68.3% |
| 2017 | Dec 29, 2017 | $63.84B | +83.9% |
| 2016 | Dec 30, 2016 | $34.72B | – |
See a number that looks wrong?